Dose Intensity

This book is devoted to the controversial topic of dose intensity for breast cancer. Over the past 15 years, there have been dozens of phase I and II clinical trials, motivated by preclinical evidence suggesting a potential therapeutic role for doses of chemotherapy sufficiently myelotoxic as to require the reinfusion of hematopoietic stem cells. Unfortunately, there is a paucity of data from prospective, randomized clinical trials to inform us adequately as to the role of this strategic ap...